TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3830763

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day (D240)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day (D360)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine 120 mg/day (N)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Verapamil 480 mg/day (V)
Number of subjects: 16
Study: 29287633

Group type: EXPERIMENTAL
Intervention: Authoritative feeding styles in low risk families
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Authoritative feeding styles in poor, food insecure, and depressed families
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Uninvolved feeding styles in poor, food insecure, and depressed families
Number of subjects: 626
Study: 26791678

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 0.5 mg kg(‐1) day(‐1) for 10 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 25623842

Group type: EXPERIMENTAL
Intervention: Patient and therapy-related factors (age, gender, bruxism, number of prostheses, time since last extraction, smoking, fit of dentures, average denture wearing time, wearing during the night)
Number of subjects: 89
Study: 23623998

Group type: EXPERIMENTAL
Intervention: Community-based lifestyle modification programme
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study: 19934621

Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention intervention
Number of subjects: 392

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 392
Study: 18375896

Group type: COMPARATOR
Intervention: Anastrozole (1 mg) for 3 months
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg) for 3 months
Number of subjects: 54
Study: 16683008

Group type: EXPERIMENTAL
Intervention: Terazosin combined with ExMI therapy (group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Terazosin monotherapy (group 1)
Number of subjects: 40
Study: 14756928

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) analgesia during physiotherapy sessions
Number of subjects: 1

Group type: COMPARATOR
Intervention: No Virtual Reality (no-VR) condition during physiotherapy sessions
Number of subjects: 1
Study: 10746444

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium, 0.1% eyedrops, 1 drop, 4 times a day for 28 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sodium chloride, 5% drops, 1 drop, 4 times a day for 28 days
Number of subjects: 32
Study: 9362654

Group type: EXPERIMENTAL
Intervention: Nurse-delivered smoking cessation intervention
Number of subjects: 0
Study: 1535082

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (21, 42, 84, and 168 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (168 micrograms)
Number of subjects: 20
Study: 3915282

Group type: EXPERIMENTAL
Intervention: CDDP
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: DDR
Number of subjects: 41
Study: 30352580

Group type: EXPERIMENTAL
Intervention: Participatory development and implementation of a community-based program to promote outdoor physical activity
Number of subjects: 8

Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 8
Study: 27220960

Group type: EXPERIMENTAL
Intervention: Sorafenib plus Erlotinib (400 mg twice daily plus 150 mg once daily)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Sorafenib plus Placebo (400 mg twice daily plus placebo)
Number of subjects: 720
Study: 25509708

Group type: EXPERIMENTAL
Intervention: Open group discussion
Number of subjects: 73

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 73
Study: 22524549

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) therapy
Number of subjects: 0
Study: 19937133

Group type: EXPERIMENTAL
Intervention: Weighted chemiluminescent membrane array (WCHMA) method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previously designed membrane array method
Number of subjects: 0
Study: 18219530

Group type: EXPERIMENTAL
Intervention: Sprayable hydrogel adhesion barrier (SprayGel)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no adhesion barrier)
Number of subjects: 40
Study: 15711353

Group type: EXPERIMENTAL
Intervention: Neoadjuvant GNRH therapy (1.2 mg per day as nasal spray for 4 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Orchiopexy alone
Number of subjects: 42
Study: 14658952

Group type: EXPERIMENTAL
Intervention: Risperidone treatment (0.02‐0.06 mg/kg/day)
Number of subjects: 700
Study: 10781483

Group type: EXPERIMENTAL
Intervention: 70 microg. kg(‐1) of ephedrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 mg. kg(‐1) esmolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8765249

Group type: EXPERIMENTAL
Intervention: Needle colposuspension
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bladder neck endopelvic fascia plication
Number of subjects: 32
Study: 1484945

Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: High fat diet
Number of subjects: 19
Study: 6424926

Group type: EXPERIMENTAL
Intervention: MMC plus oral administration of Futraful for 3 months (protocol II, group B)
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Intermittent intravenous injection of a moderate dose of MMC (protocol I, group A)
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Bolus intravenous injection of MMC (protocol II, group A)
Number of subjects: 1805
Study: 29209917

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment
Number of subjects: 860
Study: 28341959

Group type: EXPERIMENTAL
Intervention: ABP 980
Number of subjects: 157

Group type: COMPARATOR
Intervention: trastuzumab (US)
Number of subjects: 157

Group type: COMPARATOR
Intervention: trastuzumab (EU)
Number of subjects: 157
Study: 25797522

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMMCs)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 36
Study: 23279074

Group type: EXPERIMENTAL
Intervention: High DHA (∼1%)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Standard DHA (∼0.3%)
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: High DHA (∼1%) in boys
Number of subjects: 657

Group type: COMPARATOR
Intervention: Standard DHA (∼0.3%) in boys
Number of subjects: 657
Study: 21216077

Group type: EXPERIMENTAL
Intervention: Midazolam + low-dose ketamine (0.03 mg/kg midazolam + 0.3 mg/kg ketamine + saline)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Midazolam + placebo (0.03 mg/kg midazolam + 2 mL placebo)
Number of subjects: 50
Study: 18474731

Group type: EXPERIMENTAL
Intervention: Tesofensine 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tesofensine 0.25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16311076

Group type: EXPERIMENTAL
Intervention: Self-monitoring using an instrumented paper-and-pencil diary (invivodata, inc.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-monitoring (electronically recorded)
Number of subjects: 0
Study: 14551237

Group type: EXPERIMENTAL
Intervention: 40 mg/d pravastatin
Number of subjects: 27
Study: 10960382

Group type: EXPERIMENTAL
Intervention: TAPP
Number of subjects: 20

Group type: COMPARATOR
Intervention: TEP
Number of subjects: 20
Study: 8618094

Group type: EXPERIMENTAL
Intervention: Excalibur handpiece
Number of subjects: 24

Group type: COMPARATOR
Intervention: Manual hand instrumentation (K-files)
Number of subjects: 24
Study: 1599062

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.2 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 6399698

Group type: EXPERIMENTAL
Intervention: Adjuvant razoxane treatment (61 patients)
Number of subjects: 126

Group type: COMPARATOR
Intervention: No further treatment (65 patients)
Number of subjects: 126
Study: 30939778

Group type: EXPERIMENTAL
Intervention: Music therapy activities (two different types) added to standard care for 25 weekly sessions
Number of subjects: 90
Study: 29112488

Group type: EXPERIMENTAL
Intervention: RIBSP vaccine
Number of subjects: 150

Group type: COMPARATOR
Intervention: VAXIGRIP® vaccine
Number of subjects: 150
Study: 27151222

Group type: EXPERIMENTAL
Intervention: Romega® 30 (phospholipid-rich herring roe oil)
Number of subjects: 32

Group type: COMPARATOR
Intervention: TAG-rich fish oil
Number of subjects: 32
Study: 25188403

Group type: EXPERIMENTAL
Intervention: Active education group (one‐on‐one technique coaching)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Passive group (device‐specific instruction pamphlet only)
Number of subjects: 123
Study: 21842998

Group type: EXPERIMENTAL
Intervention: Graphical representations (high iconicity)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Numerical representations (low iconicity)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Graphical representations
Number of subjects: 275

Group type: COMPARATOR
Intervention: Numerical representations
Number of subjects: 275
Study: 19678756

Group type: EXPERIMENTAL
Intervention: hsCRP level > or =5 microg/mL at baseline
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: IL-6 level > or =3 pg/mL at baseline
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: hsCRP level > or =5 microg/mL (latest follow-up)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: amyloid-A level > or =6 mg/L (latest follow-up)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: IL-6 level > or =3 pg/mL (latest follow-up)
Number of subjects: 273
Study: 17195936

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 383

Group type: COMPARATOR
Intervention: Hepatitis A or B vaccines (Control)
Number of subjects: 383
Study: 15504991

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Multiple daily injections (MDII)
Number of subjects: 139
Study: 11216970

Group type: EXPERIMENTAL
Intervention: Intermittent transdermal nitroglycerin (NTG) 0.6 mg/h
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20
Study: 9850367

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms b.i.d.
Number of subjects: 482

Group type: COMPARATOR
Intervention: Salmeterol 50 micrograms b.i.d.
Number of subjects: 482
Study: 8737894

Group type: EXPERIMENTAL
Intervention: Lower energy high-fat, low-CHO meal (3181 kJ, fat:CHO energy ratio 54:41)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Higher energy low-fat, high-CHO meal (3599 kJ, fat:CHO energy ratio 7:88)
Number of subjects: 18
Study: 2201706

Group type: EXPERIMENTAL
Intervention: TTC‐WP
Number of subjects: 9

Group type: COMPARATOR
Intervention: WP only
Number of subjects: 9

Group type: COMPARATOR
Intervention: Scaling and root planing
Number of subjects: 9

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 9
Study: 6777073

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA, 1.5 g/day)
Number of subjects: 946

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 946

Group type: COMPARATOR
Intervention: Phenprocoumon
Number of subjects: 946
Study: 30380956

Group type: EXPERIMENTAL
Intervention: Oblique intradermal suture (OIS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional interrupted intradermal suture (IS)
Number of subjects: 120
Study: 27075895

Group type: EXPERIMENTAL
Intervention: Preventive home visit program (VG)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 360
Study: 23246016

Group type: EXPERIMENTAL
Intervention: Volumetric iodine-uptake (VIU) measurement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Choi criteria
Number of subjects: 15

Group type: COMPARATOR
Intervention: AASLD criteria
Number of subjects: 15
Study: 19501433

Group type: EXPERIMENTAL
Intervention: PainMatcher (PM)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 57
Study: 19390223

Group type: EXPERIMENTAL
Intervention: Treatment after 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Admission plasma tryptophan concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-treatment plasma tryptophan concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-treatment kynurenine concentrations
Number of subjects: 0
Study: 16713808

Group type: EXPERIMENTAL
Intervention: bovine organic osseous matrix (BOM) and bovine bone morphogenetic protein (bBMP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: autogenous bone graft from mandibular ramus
Number of subjects: 10
Study: 14766455

Group type: EXPERIMENTAL
Intervention: Routine follow-up in secondary care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postal questionnaire
Number of subjects: 0
Study: 11288371

Group type: EXPERIMENTAL
Intervention: Circular questioning style
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Reflexive questioning style
Number of subjects: 28

Group type: COMPARATOR
Intervention: Strategic questioning style
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lineal questioning style
Number of subjects: 28
Study: 9054789

Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral clomipramine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral clomipramine after intravenous loading
Number of subjects: 15
Study: 8477180

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of oxitropium and fenoterol
Number of subjects: 20
Study: 3080920

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition with antiphlebitic mixture (1000 IU heparin, 5 mg hydrocortisone, and 1.8 mEq sodium hydroxide as a buffer)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition without antiphlebitic mixture
Number of subjects: 54
Study: 30910355

Group type: EXPERIMENTAL
Intervention: Distance measurement between root apices and mandibular canal (MC)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Comparison of distances based on gender
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Contact or invasion of roots with MC
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Proximity of root apices to MC
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Bone density measurement
Number of subjects: 1000
Study: 29921161

Group type: EXPERIMENTAL
Intervention: Acupuncture at PC6
Number of subjects: 48

Group type: COMPARATOR
Intervention: Acupuncture at PC7
Number of subjects: 48

Group type: COMPARATOR
Intervention: Acupuncture at GB37
Number of subjects: 48

Group type: COMPARATOR
Intervention: Disgust-induced (DI) stimuli only
Number of subjects: 48
Study: 26715587

Group type: EXPERIMENTAL
Intervention: Partnered strength training (Exercising Together)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 64
Study: 24934276

Group type: EXPERIMENTAL
Intervention: Cis‐acting eSNPs
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Cis‐acting eSNPs in FADS2
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Cis‐acting eSNPs in NAGA
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Cis‐acting eSNPs in F13A1
Number of subjects: 1205
Study: 22656405

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-Ketamine combination
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dexmedetomidine-Midazolam combination
Number of subjects: 60
Study: 20399997

Group type: EXPERIMENTAL
Intervention: Enteric-coated flurbiprofen 100-mg tablet (test)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Film-coated immediate-release flurbiprofen 100-mg tablet (reference)
Number of subjects: 21
Study: 18806023

Group type: EXPERIMENTAL
Intervention: Intraoperative low-dose ketamine (bolus dose of 0.5 mg/kg followed by continuous infusion of 4 microg.kg(‐1).min(‐1))
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline (equal volume to ketamine)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intraoperative low-dose ketamine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 34
Study: 15668289

Group type: EXPERIMENTAL
Intervention: CIMV/MVAC (cisplatin, ifosphamide, methotrexate, vinblastine / methotrexate, vinblastine, doxorubicin, cisplatin)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: DC (docetaxel, cisplatin)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: ECOG performance status and haemoglobin levels
Number of subjects: 116
Study: 11807146

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 837

Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 837
Study: 10084101

Group type: EXPERIMENTAL
Intervention: Propofol infusion, 30 mg kg‐1 h‐1
Number of subjects: 42

Group type: COMPARATOR
Intervention: Propofol infusion, 30 mg kg‐1 h‐1 + fentanyl bolus, 2 micrograms kg‐1 i.v.
Number of subjects: 42
Study: 7560599

Group type: EXPERIMENTAL
Intervention: L-arginine (7 g three times daily for 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1958973

Group type: EXPERIMENTAL
Intervention: Staged fistulotomy (n = 24)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cutting seton (n = 13)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Short-term seton drainage (n = 14)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Long-term seton drainage in patients with Crohn's disease (n = 23)
Number of subjects: 74
Study: 7201089

Group type: EXPERIMENTAL
Intervention: Low-dose bromocriptine therapy (average dose, 15 mg per day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low-dose bromocriptine therapy (initial dose 1 mg per day with slow escalation)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low-dose bromocriptine therapy
Number of subjects: 25
Study: 29889581

Group type: EXPERIMENTAL
Intervention: Smoothie 1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Smoothie 2
Number of subjects: 10
Study: 28736201

Group type: EXPERIMENTAL
Intervention: Plain text message reminders
Number of subjects: 295

Group type: COMPARATOR
Intervention: Educational text message reminders
Number of subjects: 295
Study: 25994603

Group type: EXPERIMENTAL
Intervention: barnidipine+losartan
Number of subjects: 148

Group type: COMPARATOR
Intervention: telmisartan+hydrochlorothiazide
Number of subjects: 148
Study: 23869063

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine, 140 μg·kg(‐1)·min(‐1), during 5 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21640424

Group type: EXPERIMENTAL
Intervention: Intensive intervention with structured patient education (DESMOND model)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Usual care by own health professional
Number of subjects: 189
Study: 19957872

Group type: EXPERIMENTAL
Intervention: Echinacea pallida and Echinacea simulata
Number of subjects: 0
Study: 17425616

Group type: COMPARATOR
Intervention: Ropivacaine 7.5 mg/ml plus isotonic sodium chloride solution
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/ml plus 100 mg tramadol
Number of subjects: 45
Study: 15040544

Group type: EXPERIMENTAL
Intervention: didanosine-stavudine-indinavir (IDV group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: didanosine-stavudine-hydroxyurea (HU group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 11794558

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Home treatment
Number of subjects: 68
Study: 9713731

Group type: EXPERIMENTAL
Intervention: 35% oxygen until the third postoperative morning (P = prolonged group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 35% oxygen until the first postoperative morning (S = short group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 60% oxygen for 15 minutes on each of the 3 postoperative days
Number of subjects: 24
Study: 8045060

Group type: EXPERIMENTAL
Intervention: Magnesium citrate (Citramag)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Picolax
Number of subjects: 100
Study: 3409620

Group type: COMPARATOR
Intervention: Single oral dose of 200 mg of [15N]glycine as a tracer
Number of subjects: 0
Study: 31588561

Group type: EXPERIMENTAL
Intervention: PGY5 trainees
Number of subjects: 19

Group type: COMPARATOR
Intervention: PGY3 trainees
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Examination overall
Number of subjects: 19
Study: 28961980

Group type: EXPERIMENTAL
Intervention: Probiotic adjunct therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 27144828

Group type: EXPERIMENTAL
Intervention: Stem cells cultured on beta‐TCP in combination with rh‐PDGF‐BB
Number of subjects: 14

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 14
Study: 23460053

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4675

Group type: EXPERIMENTAL
Intervention: Automated
Number of subjects: 4675

Group type: EXPERIMENTAL
Intervention: Assisted
Number of subjects: 4675

Group type: EXPERIMENTAL
Intervention: Navigated
Number of subjects: 4675
Study: 21358354

Group type: EXPERIMENTAL
Intervention: Incidental durotomy group
Number of subjects: 409

Group type: COMPARATOR
Intervention: No incidental durotomy group
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 409
Study: 18305079

Group type: EXPERIMENTAL
Intervention: GIK (Glucose‐insulin‐potassium) group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 16572016

Group type: EXPERIMENTAL
Intervention: Evening removal of urinary catheters at 22:00 hours
Number of subjects: 210

Group type: COMPARATOR
Intervention: Morning removal of urinary catheters at 06:00 hours
Number of subjects: 210
Study: 14665656

Group type: EXPERIMENTAL
Intervention: Combination therapy (levothyroxine reduced by 50 micro g/d and substituted with liothyronine, 7.5 micro g, taken twice daily for 4 months)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Levothyroxine alone (usual dose)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combination therapy (levothyroxine plus liothyronine)
Number of subjects: 46
Study: 11319567

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18